Orbimed Advisors Has Upped Its Coherus Biosciences (CHRS) Position; 16 Analysts Covering Darden Restaurants, Inc. (DRI)

April 17, 2018 - By Richard Conner

Coherus BioSciences, Inc. (NASDAQ:CHRS) Logo

Orbimed Advisors Llc increased Coherus Biosciences Inc (CHRS) stake by 36.29% reported in 2017Q4 SEC filing. Orbimed Advisors Llc acquired 391,800 shares as Coherus Biosciences Inc (CHRS)’s stock rose 14.66%. The Orbimed Advisors Llc holds 1.47 million shares with $12.95 million value, up from 1.08 million last quarter. Coherus Biosciences Inc now has $779.00M valuation. The stock increased 1.57% or $0.2 during the last trading session, reaching $12.95. About 244,750 shares traded. Coherus BioSciences, Inc. (NASDAQ:CHRS) has declined 49.07% since April 17, 2017 and is downtrending. It has underperformed by 60.62% the S&P500.

Among 27 analysts covering Darden Restaurants (NYSE:DRI), 16 have Buy rating, 0 Sell and 11 Hold. Therefore 59% are positive. Darden Restaurants had 109 analyst reports since August 25, 2015 according to SRatingsIntel. As per Thursday, October 19, the company rating was maintained by BMO Capital Markets. The rating was downgraded by Credit Suisse on Tuesday, November 29 to “Neutral”. The firm earned “Buy” rating on Thursday, December 1 by Guggenheim. The rating was maintained by RBC Capital Markets with “Hold” on Friday, March 23. As per Monday, April 2, the company rating was upgraded by RBC Capital Markets. The firm earned “Hold” rating on Friday, March 23 by Deutsche Bank. The firm earned “Neutral” rating on Wednesday, October 5 by SunTrust. As per Wednesday, March 29, the company rating was downgraded by BTIG Research. The rating was maintained by Oppenheimer on Thursday, July 20 with “Buy”. RBC Capital Markets maintained the stock with “Hold” rating in Tuesday, June 27 report. See Darden Restaurants, Inc. (NYSE:DRI) latest ratings:

02/04/2018 Broker: Raymond James Rating: Buy Upgrade
02/04/2018 Broker: RBC Capital Markets Rating: Buy New Target: $97.0000 Upgrade
26/03/2018 Broker: Stephens Old Rating: Equal-Weight New Rating: Overweight Upgrade
23/03/2018 Broker: RBC Capital Markets Rating: Hold New Target: $93.0000 Maintain
23/03/2018 Broker: Barclays Capital Old Rating: Overweight New Rating: Overweight Old Target: $116 New Target: $105 Maintain
23/03/2018 Broker: Deutsche Bank Old Rating: Hold New Rating: Hold Old Target: $99 New Target: $96 Maintain
23/03/2018 Broker: BMO Capital Markets Old Rating: Market Perform New Rating: Market Perform Old Target: $99 New Target: $97 Maintain
23/03/2018 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $97 New Target: $90 Maintain
23/03/2018 Broker: Stifel Nicolaus Old Rating: Buy New Rating: Buy Old Target: $105 New Target: $100 Maintain
22/03/2018 Broker: Oppenheimer Rating: Buy New Target: $105.0000 Maintain

Orbimed Advisors Llc decreased Johnson & Johnson (NYSE:JNJ) stake by 659,100 shares to 465,300 valued at $65.01 million in 2017Q4. It also reduced Insys Therapeutics Inc New (NASDAQ:INSY) stake by 764,596 shares and now owns 5.41 million shares. Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) was reduced too.

Among 10 analysts covering Coherus Biosciences (NASDAQ:CHRS), 9 have Buy rating, 0 Sell and 1 Hold. Therefore 90% are positive. Coherus Biosciences had 20 analyst reports since September 3, 2015 according to SRatingsIntel. Cowen & Co maintained the shares of CHRS in report on Monday, June 12 with “Buy” rating. The stock has “Outperform” rating by Robert W. Baird on Wednesday, October 19. Maxim Group maintained it with “Buy” rating and $4000 target in Monday, June 12 report. Credit Suisse initiated the stock with “Outperform” rating in Wednesday, January 20 report. On Monday, November 23 the stock rating was initiated by Barclays Capital with “Overweight”. The rating was maintained by Credit Suisse on Wednesday, September 27 with “Buy”. Robert W. Baird maintained Coherus BioSciences, Inc. (NASDAQ:CHRS) on Thursday, September 7 with “Buy” rating. The company was maintained on Friday, March 9 by Maxim Group. The stock has “Buy” rating by Citigroup on Wednesday, July 27. The stock of Coherus BioSciences, Inc. (NASDAQ:CHRS) has “Buy” rating given on Friday, March 9 by Citigroup.

Investors sentiment increased to 1.16 in Q4 2017. Its up 0.09, from 1.07 in 2017Q3. It improved, as 13 investors sold CHRS shares while 24 reduced holdings. 11 funds opened positions while 32 raised stakes. 49.09 million shares or 5.36% more from 46.59 million shares in 2017Q3 were reported. Rhumbline Advisers invested in 0% or 36,197 shares. Landscape Cap Mgmt Ltd reported 0.01% stake. Meeder Asset Mngmt holds 0% or 99 shares. Manufacturers Life Insur The has 0% invested in Coherus BioSciences, Inc. (NASDAQ:CHRS) for 31,377 shares. Dekabank Deutsche Girozentrale reported 22,400 shares or 0% of all its holdings. Tiaa Cref Inv Mngmt Limited Liability Corporation stated it has 1.04M shares or 0.01% of all its holdings. Commercial Bank Of Ny Mellon Corp invested 0% in Coherus BioSciences, Inc. (NASDAQ:CHRS). Ubs Asset Mgmt Americas reported 1.39 million shares. State Board Of Administration Of Florida Retirement System stated it has 17,763 shares. Moreover, Credit Suisse Ag has 0% invested in Coherus BioSciences, Inc. (NASDAQ:CHRS) for 111,704 shares. Citigroup owns 0% invested in Coherus BioSciences, Inc. (NASDAQ:CHRS) for 38,331 shares. Goldman Sachs Group Inc holds 339,480 shares. Kennedy Cap Mgmt Incorporated has invested 0.02% in Coherus BioSciences, Inc. (NASDAQ:CHRS). Federated Investors Incorporated Pa has 1,431 shares. Td Asset Management stated it has 15,671 shares.

Darden Restaurants, Inc., through its subsidiaries, owns and operates full-service restaurants in the United States and Canada. The company has market cap of $11.07 billion. As of June 27, 2017, it owned and operated approximately 1,700 restaurants under the Olive Garden, LongHorn Steakhouse, Cheddar's Scratch Kitchen, Yard House, The Capital Grille, Seasons 52, Bahama Breeze, and Eddie V's brands. It has a 20.69 P/E ratio.

Since January 10, 2018, it had 0 buys, and 3 sales for $7.25 million activity. Shares for $417,315 were sold by Milanes Douglas J.. Cardenas Ricardo had sold 10,783 shares worth $1.05 million on Wednesday, January 10. LEE EUGENE I JR sold $5.79 million worth of stock.

Investors sentiment decreased to 0.88 in Q4 2017. Its down 0.08, from 0.96 in 2017Q3. It turned negative, as 46 investors sold Darden Restaurants, Inc. shares while 187 reduced holdings. 83 funds opened positions while 121 raised stakes. 103.03 million shares or 4.63% less from 108.03 million shares in 2017Q3 were reported. Bnp Paribas Arbitrage Sa invested in 0.02% or 111,299 shares. Panagora Asset reported 19,731 shares. Smithfield Tru Com reported 0% of its portfolio in Darden Restaurants, Inc. (NYSE:DRI). Whitnell And Communications reported 0.01% stake. First City Capital Mgmt Incorporated holds 7,500 shares or 0.49% of its portfolio. Synovus Fincl Corp stated it has 0.21% in Darden Restaurants, Inc. (NYSE:DRI). Cetera Advsrs Lc reported 2,762 shares or 0.02% of all its holdings. Cullen Frost Bankers Incorporated owns 4,924 shares. Coastline Trust owns 0.22% invested in Darden Restaurants, Inc. (NYSE:DRI) for 15,490 shares. Public Employees Retirement Association Of Colorado invested in 0.02% or 24,797 shares. Cubist Systematic Strategies Limited Liability Co invested in 21,545 shares or 0.11% of the stock. Moody Bankshares Trust Division reported 0.05% in Darden Restaurants, Inc. (NYSE:DRI). Ahl Prtn Llp accumulated 143,139 shares or 0.21% of the stock. Amica Retiree Medical Tru reported 702 shares stake. Ontario – Canada-based Omers Administration has invested 0.03% in Darden Restaurants, Inc. (NYSE:DRI).

Darden Restaurants, Inc. (NYSE:DRI) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>